The prognostic value of hematogones in patients with acute myeloid leukemia |
| |
| Authors: | Sylvain P. Chantepie Jean‐Jacques Parienti Véronique Salaun Khaled Benabed Stéphane Cheze Anne‐Claire Gac Hyacinthe Johnson‐Ansah Margaret Macro Gandhi Damaj Jean‐Pierre Vilque Oumedaly Reman |
| |
| Affiliation: | 1. Department of Hematology, CHU Caen, Cote de Nacre Avenue, France;2. Department of Biostatistics and Clinical Research, CHU Caen, Cote de Nacre Avenue, France;3. Caen Normandie University, Medical school, Caen, France;4. Hematology Laboratory, CHU Caen, Cote de Nacre Avenue, France;5. Department of Hematology, Baclesse Cancer Centre, Caen, General Harris Avenue, France |
| |
| Abstract: | In acute myeloid leukemia (AML), new prognostic tools are needed to assess the risk of relapse. Hematogones (HGs) are normal B‐lymphocyte precursors that increase in hematological diseases and may influence remission duration in AML. HG detection was prospectively investigated in 262 AML patients to determine its prognostic value. Flow cytometric HG detection was performed in bone marrow aspiration after intensive chemotherapy at the time of hematological recovery. Patients with HGs in bone marrow samples had a significantly better relapse‐free survival (RFS) and overall survival (OS) than patients without HGs (P = 0.0021, and P = 0.0016). Detectable HGs independently predicted RFS (HR = 0.61, 95%CI: 0.42 ? 0.89, P = 0.012) and OS (HR = 0.59, 95%CI: 0.38 ? 0.92, 0.019) controlling for age, ELN classification, the number of chemotherapy cycles to achieve CR, performance status, secondary AML and flow cytometric minimal residual disease (MRD). In intensively treated AML, individual determination of HGs could be useful to stratify the optimal risk‐adapted therapeutic strategy after induction chemotherapy. Am. J. Hematol. 91:566–570, 2016. © 2016 Wiley Periodicals, Inc. |
| |
| Keywords: | |
|
|
